These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

828 related articles for article (PubMed ID: 18664927)

  • 1. FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks.
    Figueras-Aloy J; Carbonell-Estrany X; Quero-Jiménez J; Fernández-Colomer B; Guzmán-Cabañas J; Echaniz-Urcelay I; Doménech-Martínez E;
    Pediatr Infect Dis J; 2008 Sep; 27(9):788-93. PubMed ID: 18664927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of severe disease caused by respiratory syncytial virus in children living in developed countries.
    Simoes EA; Carbonell-Estrany X
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S13-8; discussion S18-20. PubMed ID: 12671448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
    Pedraz C; Carbonell-Estrany X; Figueras-Aloy J; Quero J;
    Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain.
    Figueras-Aloy J; Carbonell-Estrany X; Quero J;
    Pediatr Infect Dis J; 2004 Sep; 23(9):815-20. PubMed ID: 15361718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Usefulness of different risk factor associations in predicting admissions due to respiratory syncytial virus in premature newborns of 32 to 35 weeks gestation in Spain].
    Figueras-Aloy J; Quero-Jiménez J; Fernández-Colomer B; Guzmán-Cabañas J; Echaniz-Urcelay I; Doménech-Martínez E;
    An Pediatr (Barc); 2009 Jul; 71(1):47-53. PubMed ID: 19524492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Respiratory syncytial virus risk factors in late preterm infants.
    Lanari M; Silvestri M; Rossi GA
    J Matern Fetal Neonatal Med; 2009; 22 Suppl 3():102-7. PubMed ID: 19925369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
    Stevens TP; Sinkin RA; Hall CB; Maniscalco WM; McConnochie KM
    Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
    Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada.
    Paes B; Steele S; Janes M; Pinelli J
    Curr Med Res Opin; 2009 Jul; 25(7):1585-91. PubMed ID: 19469698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Total healthcare costs in the US for preterm infants with respiratory syncytial virus lower respiratory infection in the first year of life requiring medical attention.
    Stewart DL; Romero JR; Buysman EK; Fernandes AW; Mahadevia PJ
    Curr Med Res Opin; 2009 Nov; 25(11):2795-804. PubMed ID: 19788406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
    Romero JR
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and validation of a risk scoring tool to predict respiratory syncytial virus hospitalization in premature infants born at 33 through 35 completed weeks of gestation.
    Sampalis JS; Langley J; Carbonell-Estrany X; Paes B; O'Brien K; Allen U; Mitchell I; Aloy JF; Pedraz C; Michaliszyn AF
    Med Decis Making; 2008; 28(4):471-80. PubMed ID: 18556643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of respiratory syncytial virus infection in Italian infants hospitalized for acute lower respiratory tract infections, and association between respiratory syncytial virus infection risk factors and disease severity.
    Lanari M; Giovannini M; Giuffré L; Marini A; Rondini G; Rossi GA; Merolla R; Zuccotti GV; Salvioli GP;
    Pediatr Pulmonol; 2002 Jun; 33(6):458-65. PubMed ID: 12001280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Respiratory syncytial virus infection--risk factors for hospital admission: a case-control study.
    Nielsen HE; Siersma V; Andersen S; Gahrn-Hansen B; Mordhorst CH; Nørgaard-Pedersen B; Røder B; Sørensen TL; Temme R; Vestergaard BF
    Acta Paediatr; 2003 Nov; 92(11):1314-21. PubMed ID: 14696852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rehospitalisations for respiratory disease and respiratory syncytial virus infection in preterm infants of 29-36 weeks gestational age.
    Resch B; Pasnocht A; Gusenleitner W; Müller W
    J Infect; 2005 Jun; 50(5):397-403. PubMed ID: 15907547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis.
    Heikkinen T; Valkonen H; Lehtonen L; Vainionpää R; Ruuskanen O
    Arch Dis Child Fetal Neonatal Ed; 2005 Jan; 90(1):F64-8. PubMed ID: 15613580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The risk of respiratory syncytial virus-related hospitalizations in preterm infants of 29 to 35 weeks' gestational age.
    Doering G; Gusenleitner W; Belohradsky BH; Burdach S; Resch B; Liese JG
    Pediatr Infect Dis J; 2006 Dec; 25(12):1188-90. PubMed ID: 17133170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Palivizumab outcomes registry data from Spain: Infección Respiratoria Infantil por Virus Respiratorio Sincitial (IRIS) Study Group.
    Carbonell-Estrany X
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S55-7; discussion S57. PubMed ID: 12671453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology of respiratory syncytial virus infection in infants born at less than thirty-five weeks of gestational age.
    Park HW; Lee BS; Kim AR; Yoon HS; Kim BI; Song ES; Kim WT; Lim J; Kim S; Jin HS; Byun S; Chee DH; Kim KS
    Pediatr Infect Dis J; 2012 Aug; 31(8):e99-104. PubMed ID: 22531234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrent wheezing in the third year of life among children born at 32 weeks' gestation or later: relationship to laboratory-confirmed, medically attended infection with respiratory syncytial virus during the first year of life.
    Escobar GJ; Ragins A; Li SX; Prager L; Masaquel AS; Kipnis P
    Arch Pediatr Adolesc Med; 2010 Oct; 164(10):915-22. PubMed ID: 20921348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.